Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

IMMUNOTHERAPY

Inserting EF1α-driven CD7-specific CAR at CD7 locus reduces fratricide and enhances tumor rejection

Leukemia volume 37, pages 1660–1670 (2023)Cite this article

Subjects

Abstract

CAR-T therapies to treat T-cell malignancies face unique hurdles. Normal and malignant T cells usually express the same target for CAR, leading to fratricide. CAR-T cells targeting CD7, which is expressed in various malignant T cells, have limited expansion due to fratricide. Using CRISPR/Cas9 to knockout CD7 can reduce the fratricide. Here we developed a 2-in-1 strategy to insert EF1α-driven CD7-specific CAR at the disrupted CD7 locus and compared it to two other known strategies: one was random integration of CAR by a retrovirus and the other was site-specific integration at T-cell receptor alpha constant (TRAC) locus, both in the context of CD7 disruption. All three types of CD7 CAR-T cells with reduced fratricide could expand well and displayed potent cytotoxicity to both CD7+ tumor cell lines and patient-derived primary tumors. Moreover, EF1α-driven CAR expressed at the CD7 locus enhances tumor rejection in a mouse xenograft model of T-cell acute lymphoblastic leukemia (T-ALL), suggesting great clinical application potential. Additionally, this 2-in-1 strategy was adopted to generate CD7-specific CAR-NK cells as NK also expresses CD7, which would prevent contamination from malignant cells. Thus, our synchronized antigen-knockout CAR-knockin strategy could reduce the fratricide and enhance anti-tumor activity, advancing clinical CAR-T treatment of T-cell malignancies.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Potent cytotoxicity coincided with fratricide of CD7 CAR-T cells.
Fig. 2: A 2-in-1 strategy to produce expandable and functional CD7KO CAR-T cells.
Fig. 3: Anti-tumor activity of CD7KO CAR-T cells against primary T-ALL blasts.
Fig. 4: CD7KO CAR-T cells control the progression of T-ALL in the mouse xenograft model.
Fig. 5: The 2-in-1 strategy generated CAR-NK cells with anti-tumor activity.

Similar content being viewed by others

References

  1. June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018;379:64–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Park JH, Riviere I, Gonen M, Wang X, Senechal B, Curran KJ, et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med. 2018;378:449–59.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, et al. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019;380:1726–37.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Fleischer LC, Spencer HT, Raikar SS. Targeting T cell malignancies using CAR-based immunotherapy: challenges and potential solutions. J Hematol Oncol. 2019;12:141.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Ware RE, Scearce RM, Dietz MA, Starmer CF, Palker TJ, Haynes BF. Characterization of the surface topography and putative tertiary structure of the human CD7 molecule. J Immunol. 1989;143:3632–40.

    Article  CAS  PubMed  Google Scholar 

  6. Wenzinger C, Williams E, Gru AA. Updates in the pathology of precursor lymphoid neoplasms in the revised fourth edition of the who classification of tumors of hematopoietic and lymphoid tissues. Curr Hematol Malig Rep. 2018;13:275–88.

    Article  PubMed  Google Scholar 

  7. Baum W, Steininger H, Bair HJ, Becker W, Hansen-Hagge TE, Kressel M, et al. Therapy with CD7 monoclonal antibody TH‐69 is highly effective for xenografted human. Br J Haematol. 1996;95:327–38.

    Article  CAS  PubMed  Google Scholar 

  8. Pauza ME, Doumbia SO, Pennell CA. Construction and characterization of human CD7-specific single-chain Fv immunotoxins. J Immunol. 1997;158:3259–69.

    Article  CAS  PubMed  Google Scholar 

  9. Uckun FM, Ramakrishnan S, Houston LL. Immunotoxin-mediated elimination of clonogenic tumor cells in the presence of human bone marrow. J Immunol. 1985;134:2010–6.

    Article  CAS  PubMed  Google Scholar 

  10. Zhang J, Jain A, Milhas S, Williamson DJ, Mysliwy J, Lodge A, et al. An antibody-drug conjugate with intracellular drug release properties showing specific cytotoxicity against CD7-positive cells. Leuk Res. 2021;108:106626.

    Article  CAS  PubMed  Google Scholar 

  11. Yu Y, Li J, Zhu X, Tang X, Bao Y, Sun X, et al. Humanized CD7 nanobody-based immunotoxins exhibit promising anti-T-cell acute lymphoblastic leukemia potential. Int J Nanomed. 2017;12:1969–83.

    Article  CAS  Google Scholar 

  12. Brammer JE, Saliba RM, Jorgensen JL, Ledesma C, Gaballa S, Poon M, et al. Multi-center analysis of the effect of T-cell acute lymphoblastic leukemia subtype and minimal residual disease on allogeneic stem cell transplantation outcomes. Bone Marrow Transpl. 2017;52:20–7.

    Article  CAS  Google Scholar 

  13. Litzow MR, Ferrando AA. How I treat T-cell acute lymphoblastic leukemia in adults. Blood. 2015;126:833–41.

    Article  CAS  PubMed  Google Scholar 

  14. Bayon-Calderon F, Toribio ML, Gonzalez-Garcia S. Facts and challenges in immunotherapy for T-cell acute lymphoblastic leukemia. Int J Mol Sci. 2020;21:7685.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. U.S. National Library of Medicine. ClinicalTrials. https://clinicaltrials.gov.

  16. Pan J, Tan Y, Wang G, Deng B, Ling Z, Song W, et al. Donor-derived CD7 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia: first-in-human, phase I trial. J Clin Oncol. 2021;39:3340–52.

    Article  CAS  PubMed  Google Scholar 

  17. Teachey DT, Hunger SP. Anti-CD7 CAR T cells for T-ALL: impressive early-stage efficacy. Nat Rev Clin Oncol. 2021;18:677–8.

    Article  CAS  PubMed  Google Scholar 

  18. Gomes-Silva D, Srinivasan M, Sharma S, Lee CM, Wagner DL, Davis TH, et al. CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. Blood 2017;130:285–96.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Mamonkin M, Mukherjee M, Srinivasan M, Sharma S, Gomes-Silva D, Mo F, et al. Reversible transgene expression reduces fratricide and permits 4-1BB costimulation of CAR T cells directed to T-cell malignancies. Cancer Immunol Res. 2018;6:47–58.

    Article  CAS  PubMed  Google Scholar 

  20. Rasaiyaah J, Georgiadis C, Preece R, Mock U, Qasim W. TCRalphabeta/CD3 disruption enables CD3-specific antileukemic T cell immunotherapy. JCI Insight. 2018;3:e99442.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Cooper ML, Choi J, Staser K, Ritchey JK, Devenport JM, Eckardt K, et al. An “off-the-shelf” fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies. Leukemia 2018;32:1970–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Georgiadis C, Rasaiyaah J, Gkazi SA, Preece R, Etuk A, Christi A, et al. Base-edited CAR T cells for combinational therapy against T cell malignancies. Leukemia. 2021;35:3466–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Gomes-Silva D, Atilla E, Atilla PA, Mo F, Tashiro H, Srinivasan M, et al. CD7 CAR T Cells for the therapy of acute myeloid leukemia. Mol Ther. 2019;27:272–80.

    Article  CAS  PubMed  Google Scholar 

  24. Png YT, Vinanica N, Kamiya T, Shimasaki N, Coustan-Smith E, Campana D. Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies. Blood Adv. 2017;1:2348–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Freiwan A, Zoine J, Crawford JC, Vaidya A, Schattgen SA, Myers J, et al. Engineering naturally occurring CD7 negative T cells for the immunotherapy of hematological malignancies. Blood 2022;140:2684–96.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Wang X, Riviere I. Clinical manufacturing of CAR T cells: foundation of a promising therapy. Mol Ther Oncol. 2016;3:16015.

    Article  CAS  Google Scholar 

  27. Ellis DJ. Silencing and variegation of gammaretrovirus and lentivirus vectors. Hum Gene Ther. 2005;16:1241–6.

    Article  CAS  PubMed  Google Scholar 

  28. Eyquem J, Mansilla-Soto J, Giavridis T, van der Stegen SJ, Hamieh M, Cunanan KM, et al. Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection. Nature. 2017;543:113–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Melenhorst JJ, Chen GM, Wang M, Porter DL, Chen C, Collins MA, et al. Decade-long leukaemia remissions with persistence of CD4(+) CAR T cells. Nature. 2022;602:503–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Mayer KE, Mall S, Yusufi N, Gosmann D, Steiger K, Russelli L, et al. T-cell functionality testing is highly relevant to developing novel immuno-tracers monitoring T cells in the context of immunotherapies and revealed CD7 as an attractive target. Theranostics. 2018;8:6070–87.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Gattinoni L, Lugli E, Ji Y, Pos Z, Paulos CM, Quigley MF, et al. A human memory T cell subset with stem cell-like properties. Nat Med. 2011;17:1290–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Gu Y, Zhang J, Ma X, Kim BW, Wang H, Li J, et al. Stabilization of the c-Myc protein by CAMKIIgamma promotes T cell lymphoma. Cancer Cell. 2017;32:115–28.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Lu P, Liu Y, Yang J, Zhang X, Yang X, Wang H, et al. Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL/LBL: first-in-human phase 1 clinical trial. Blood. 2022;140:321–34.

    CAS  PubMed  Google Scholar 

  34. Pan J, Tan Y, Wang G, Deng B, Ling Z, Song W, et al. Donor-derived CD7 chimeric antigen receptor T cells for T-cell acute lymphoblastic leukemia: first-in-human, phase I trial. J Clin Oncol. 2021;39:3340–51.

    Article  CAS  PubMed  Google Scholar 

  35. Tan Y, Shan L, Zhao L, Deng B, Ling Z, Zhang Y, et al. Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblastic leukemia. J Hematol Oncol. 2023;16:34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Duan Y, Chen R, Huang Y, Meng X, Chen J, Liao C, et al. Tuning the ignition of CAR: optimizing the affinity of scFv to improve CAR-T therapy. Cell Mol Life Sci. 2021;79:14.

    Article  PubMed  Google Scholar 

  37. Xiao Q, Zhang X, Tu L, Cao J, Hinrichs CS, Su X. Size-dependent activation of CAR-T cells. Sci Immunol. 2022;7:eabl3995.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Depil S, Duchateau P, Grupp SA, Mufti G, Poirot L. ‘Off-the-shelf’ allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020;19:185–99.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors thank the support of Zhejiang Provincial Key Laboratory of Immunity and Inflammatory Diseases, and thank Yueting Xin, Chun Guo, Jiajia Wang, Yingying Huang from the core facilities, Zhejiang University School of Medicine for their technical support.

Funding

This research was funded by the National Key R&D Program of China 2021YFA0909900 (JS), 2018YFA0800102 (YG), the National Natural Science Foundation of China grants 31971324 (JS), 31970555 (YG), 82161138028 (JS), 81973993 (XG), Zhejiang Provincial Natural Science Foundation grant LR20H160003 (JS), LR20C070001 (XG) and the Leading Innovative and Entrepreneur Team Introduction Program of Zhejiang grant 2020R01006 (JS, YG).

Author information

Authors and Affiliations

  1. Bone Marrow Transplantation Center of the First Affiliated Hospital and Department of Cell Biology, Zhejiang University School of Medicine, 866 Yuhangtang Road, Hangzhou, 310058, China

    Jie Jiang, Jiangqing Chen, Yanting Duan, Yajie Wang, Kai Shang & Jie Sun

  2. Liangzhu Laboratory, Zhejiang University Medical Center, 1369 West Wenyi Road, Hangzhou, 311121, China

    Jie Jiang, Jiangqing Chen, Yanting Duan, Yajie Wang, Kai Shang, Ying Gu & Jie Sun

  3. Institute of Hematology, Zhejiang University & Zhejiang Engineering Laboratory for Stem Cell and Immunotherapy, Hangzhou, 310058, Zhejiang, China

    Jie Jiang, Jiangqing Chen, Yanting Duan, Yajie Wang, Kai Shang & Jie Sun

  4. Department of Hematology-oncology, Children’s Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

    Chan Liao & Yongming Tang

  5. Key Laboratory of Structural Biology of Zhejiang Province, School of Life Sciences, Westlake University, Hangzhou, 310058, China

    Yanjie Huang & Xiaofei Gao

  6. Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), the Second Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou, Zhejiang, 310009, China

    Ying Gu

  7. Institute of Genetics, Zhejiang University and Department of Genetics, Zhejiang University, School of Medicine, Hangzhou, 310058, China

    Ying Gu

  8. Zhejiang Provincial Key Lab of Genetic and Developmental Disorder, Hangzhou, Zhejiang, 310058, China

    Ying Gu

Authors
  1. Jie Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jiangqing Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chan Liao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yanting Duan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yajie Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Kai Shang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yanjie Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yongming Tang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Xiaofei Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Ying Gu
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Jie Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

JJ and JS designed the studies and conceived the experiments. JJ, JC, and YW performed most of the experiments; CL, DY, KS conducted data analysis; YH, YT, and XG contributed reagents. JJ, YG, and JS wrote the manuscript. YG and JS supervised the study. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Ying Gu or Jie Sun.

Ethics declarations

Competing interests

The authors declare no competing interests.

Ethics approval and consent to participate

All animal studies were reviewed and approved by the Ethical Committee of Westlake University.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jiang, J., Chen, J., Liao, C. et al. Inserting EF1α-driven CD7-specific CAR at CD7 locus reduces fratricide and enhances tumor rejection. Leukemia 37, 1660–1670 (2023). https://doi.org/10.1038/s41375-023-01948-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41375-023-01948-3

This article is cited by

Search

Advanced search

Quick links